Nancy Wong
Sanofi (United States)(US)
Publications by Year
Research Areas
Platelet Disorders and Treatments, Blood groups and transfusion, Cancer Treatment and Pharmacology, Hemophilia Treatment and Research, Erythrocyte Function and Pathophysiology
Most-Cited Works
- → A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies(2009)144 cited
- → Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol®-PM) in patients with solid tumors(2009)139 cited
- → The contribution of de novo and rare inherited copy number changes to congenital heart disease in an unselected sample of children with conotruncal defects or hypoplastic left heart disease(2013)117 cited
- → Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial(2022)107 cited
- → Safety, Pharmacokinetics, Pharmacodynamics, and Plasma Lipoprotein Distribution of Eritoran (E5564) during Continuous Intravenous Infusion into Healthy Volunteers(2004)73 cited
- → Sustained Accumulation of Microtubule-Binding Chemotherapy Drugs in the Peripheral Nervous System: Correlations with Time Course and Neurotoxic Severity(2016)52 cited
- → Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel γ-secretase modulator, E2212, in healthy human subjects(2013)41 cited
- → Discovery of a potent, metabolically stabilized resorcylic lactone as an anti-inflammatory lead(2009)28 cited
- → Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers(2008)22 cited
- → First‐in‐human study with SAR445088: A novel selective classical complement pathway inhibitor(2023)19 cited